Answers are grounded in this paper and cite their sources.
BACKGROUND: Based on the role of bone marrow (BM) stem cells in regeneration of endometrium, refractory cases of Asherman's syndrome (AS) and endometrial atrophy (EA) may benefit with BM-derived intrauterine stem cell instillation. Aims and Objectives: To evaluate the role of BM-derived autologous stem cell therapy in endometrial regeneration and restoration of menstruation and fertility in refractory cases of AS and EA. SETTING: This study was conducted at a tertiary care center. DESIGN: This was a prospective, single-arm longitudinal study. MATERIALS AND METHODS: Twenty-five cases with refractory AS or EA were included. BM-derived mononuclear stem cells were instilled into the subendometrial zone followed by oral estrogen therapy for 3 months. Menstrual flow and endometrial thickness (ET) were assessed at 3, 6, and 9 months and 5 years. Six of the seven amenorrheic patients resumed menses. Three patients had a successful pregnancy outcome. CONCLUSION: Intrauterine stem cell treatment is a promising novel approach for refractory cases of AS and EA.
No takes yet. Share an insight, caveat, or question.
Singh et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: